Head-to-head evidence
DNV001 vs Ebronucimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
DNV001
Developed by Hangzhou Dinovate Biotech
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07391722 (registry estimate)
Ebronucimab
Developed by Akeso
NCT05255094 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. However, its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome, and the registry does not report whether the comparison was favorable or statistically significant.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DNV001's landscape · Ebronucimab's landscape